Zenagamtide vs CagriSema: Single Molecule vs Fixed-Dose Combination

Are Zenagamtide and CagriSema the Same Drug?

Short answer: no. They share a mechanism of action — dual activation of GLP-1 and amylin receptors — and they share a developer in Novo Nordisk. Past that, the two compounds diverge. Zenagamtide, also known as amycretin, is a single unimolecular peptide engineered so that one molecular backbone activates both receptor families. CagriSema is a fixed-dose combination: two separate peptides — cagrilintide (a long-acting amylin analog) and semaglutide (the GLP-1 receptor agonist already on market as Ozempic and Wegovy) — co-formulated into a single subcutaneous injection.

That distinction is more than academic. It changes manufacturing complexity, dosing flexibility, pharmacokinetics, and how each program can extend over the next decade. Two competing answers to the same biological question, both running inside the same company.

What Is Zenagamtide (Amycretin)?

Zenagamtide is Novo Nordisk’s unimolecular dual GLP-1/amylin receptor agonist — a single peptide built to activate both receptor families simultaneously. It is being evaluated for obesity and type 2 diabetes across a slate of trials initiated through 2024 and 2025. In the published Phase 1b/2 readout, subcutaneous zenagamtide produced approximately 22% mean weight loss over roughly 36 weeks. Our zenagamtide compound profile walks through the mechanism, trial enrollment, and dose-escalation data in detail.

The more strategically important asset may be the oral formulation. Novo Nordisk has an oral version of zenagamtide in Phase 2 under NCT06490861 and NCT06490874. If those trials read out positively, zenagamtide would be one of the first oral dual GLP-1/amylin agonists to reach the market — a meaningful structural advantage over any injection-only competitor, including CagriSema. Zenagamtide also holds an orphan drug designation alongside its broader obesity development program.

What Is CagriSema?

CagriSema is Novo Nordisk’s fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), delivered as a single weekly subcutaneous injection. The Phase 3 REDEFINE program reported 22.7% mean weight loss in REDEFINE 1 (obesity, no diabetes) and 15.7% in REDEFINE 2 (type 2 diabetes).

Novo Nordisk filed the New Drug Application (NDA) with the FDA on December 18, 2025 — the company’s most advanced dual-receptor obesity asset and the first once-weekly GLP-1/amylin combination to reach a regulatory submission. An FDA decision is expected in late 2026. Because CagriSema is a fixed-dose combination, the cagrilintide-to-semaglutide ratio is locked at the formulation level: clinicians can move the total dose, but they cannot tune the two components independently. The full REDEFINE dataset is broken down in our CagriSema profile.

How Do Their Approaches Differ?

Architecturally, the two programs sit on opposite sides of a design choice. CagriSema is a co-formulation play: take two molecules with substantial independent clinical evidence (cagrilintide and semaglutide), set a fixed ratio, and put them in one syringe. The upside is that both components arrive with their own safety and efficacy histories. The downside is that the ratio is locked, and the manufacturing line has to produce, purify, and stabilize two peptides instead of one.

Zenagamtide is the inverse: rather than combining two molecules, engineer a single peptide with both activities encoded into one structure. The receptor balance is built into the molecule rather than negotiated by mixing. The trade-off is that the molecule is novel, the chemistry is more demanding, and the clinical record is still in Phase 1b/2 — Phase 3 has not yet started. For how both compare against next-generation triple agonists, see our retatrutide vs tirzepatide vs CagriSema breakdown.

Why Does the Single-Molecule Design Matter?

Three downstream advantages flow from packing both activities into one peptide. Manufacturing is simpler — there is only one molecule to synthesize, purify, and characterize, instead of two separate active pharmaceutical ingredients held to a strict combination spec. Pharmacokinetic optimization is cleaner because both effects ride the same absorption and clearance profile, rather than relying on two molecules with potentially divergent half-lives.

The biggest payoff, though, is oral delivery. Building an oral version of a fixed-dose combination would mean solving the oral absorption problem twice — once for each peptide — and then preserving a fixed ratio across both. A single molecule sidesteps that. Zenagamtide’s oral Phase 2 program is the practical demonstration: the unimolecular design is what makes the oral pathway tractable. For an amylin-only counterpoint, see our petrelintide research breakdown.

What Does This Mean for Novo Nordisk’s Pipeline?

Novo Nordisk is running a deliberate two-generation strategy. CagriSema is the near-term commercial bet — NDA filed, Phase 3 dataset complete, FDA decision expected late 2026. It is positioned to compete head-on with tirzepatide (Zepbound and Mounjaro) and to defend the existing Wegovy franchise as the GLP-1/amylin entrant.

Zenagamtide is the long-horizon platform. It is years from any regulatory filing, but its unimolecular design and oral development program give it a clear successor profile. If the Phase 3 readouts confirm that one molecule can match or beat a two-molecule combination — particularly in oral form — zenagamtide could become Novo Nordisk’s preferred GLP-1/amylin asset over the next decade.

Running a near-term program and a next-generation successor in the same indication is standard pharmaceutical strategy. It hedges the launch risk on CagriSema, gives Novo Nordisk a structural lead in the oral GLP-1/amylin race, and keeps the company in step with the broader incretin pipeline. For the wider competitive landscape, see our obesity drug approval tracker 2026 and the best obesity drug 2026 comparison.